VaLogic

Out-of-specification. Out-of-trend. Two different signals. Two different responses.

OOS (Out-of-Specification) A result falls outside the established acceptance criteria defined in the specification. This triggers a mandatory, documented two-phase investigation under 21 CFR 211.192. The batch cannot be released until the investigation is complete and a disposition decision is made.

OOT (Out-of-Trend) A result is within specification but deviating from the expected statistical pattern over time. No regulatory mandate requires a specific investigation format but ignoring OOT results is how OOS results arrive without warning.

The practical distinction: OOS results are a compliance event. OOT results are an early warning system.

Organizations that only respond to OOS findings are managing compliance reactively. Organizations that track OOT data are managing quality proactively.

The FDA expects both. Warning letters cite missing trending programs with the same regularity they cite inadequate OOS investigations.

Does your quality system treat OOT data as a leading indicator, or does it wait for a specification exceedance before generating a record?

Approving a supplier is the beginning of the quality relationship, not the end of it.

Yet most supplier quality programs invest heavily in initial qualification and almost nothing in what comes after: ongoing performance monitoring, periodic re-qualification, and the triggered reviews that a major quality event or regulatory finding should automatically initiate.

The pattern that creates risk: a supplier qualifies cleanly, gets added to the Approved Vendor List, and is never formally reassessed unless something goes wrong. By the time something goes wrong, the gap in oversight is already a finding.

A compliant supplier qualification program treats approval as a living status. Lot rejection rates, CAPA responsiveness, audit outcomes, and change notifications are not administrative data points; they are the evidence base for a supplier's continued approval.

Approved status should be continuously earned, not permanently granted.

Two questions worth asking about your current program:

-When was the last time a supplier was formally re-qualified — not just audited, but re-evaluated against your current quality requirements?

And if a critical supplier had a significant quality event last quarter, would your system automatically trigger a reassessment, or would it wait for the next scheduled review?

-How does your organization structure ongoing supplier oversight?

Follow VaLogic for GMP compliance insights.

Celebrating Independence Day 🇺🇸

This 4th of July, we at VaLogic Bio are taking a moment to reflect on the principles of innovation, resilience, and freedom that define our nation.

We are incredibly grateful for our dedicated team, our valued clients, and our trusted colleagues who make our work possible every day.

Please note: Our offices will be closed on Friday, July 3rd, in observance of the holiday. We will resume normal operations on Monday, July 6th.

Wishing everyone a safe, happy, and relaxing holiday weekend! 🎆

Moving from paper to an electronic lab notebook is a compliance upgrade, but only if the implementation is done correctly.

It is a compliance liability if it is not.

The most common ELN implementation failures:

-No audit trail validation. An ELN must generate a complete, unalterable audit trail. If your validation protocol did not verify that the audit trail cannot be modified or deleted by standard users, you have a gap.

-User access not mapped to roles. Analysts should not have the ability to approve their own entries. Reviewers should not be able to enter raw data. Access controls must mirror your organizational quality roles.

-Parallel paper records still in use. Transitioning to ELN while maintaining paper backups creates two records of truth. That is not a safety net. That is a data integrity problem.

-Legacy data migration without a protocol. Importing historical records without a validated migration process introduces unverifiable data into a compliant system.

The platform is not the compliance program. Your procedures, training, and controls are.

What phase of ELN implementation creates the most compliance exposure in your experience?

Follow VaLogic for GMP compliance insights.